AVITA Medical is an acute wound-care company trying to prove that last year's reimbursement shock is over and that a thinner cost base can carry the franchise to cash-flow breakeven before the cash pile runs out. The second-quarter print delivered the first result above $20 million and a raise of full-year revenue guidance. That is the operating proof. The investment debate is not whether RECELL still works in the burn bay. It is whether sequential growth and a collapsing cash burn can close the gap to self-funding before a going-concern warning and a secured lender become the story again.
The tension sits in the cash account, not the income statement. Revenue grew on RECELL utilization after all 7 Medicare contractors published clinician rates, while Cohealyx and PermeaDerm began to attach as a wound-prep and temporizing layer. Operating expenses fell even as the top line rose, which is the leverage the prior-year commercial reset was supposed to produce. Net cash use dropped sharply from the first quarter. Yet quarter-end cash and marketable securities were only about $11 million against a loan facility near $47 million and an explicit going-concern paragraph in the mid-year filing.
The market has already paid up for the recovery. Shares that traded near $4 at mid-year closed at $11.02 on the publication date, near the top of the yearly range. What remains unproven is the fourth-quarter cash-flow crossing itself. Does third-quarter sequential growth keep cash use shrinking, or does a seasonal pause force another capital raise against a $5 million minimum-cash covenant?